Yonggang Huang, Xiaosheng Lu, Zhaoxia Huang, Yilu Chen, Jiqiang Lv, Huina Zhang
Reproductive Medicine Center, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
Saudi J Biol Sci. 2017 Feb;24(2):241-245. doi: 10.1016/j.sjbs.2016.09.011. Epub 2016 Sep 9.
Effects of human chorionic gonadotropin combined with clomiphene on serum E, FSH, LH and PRL levels in patients with polycystic ovarian syndrome were analyzed.
90 patients with polycystic ovarian syndrome treated from January 2015 to March 2016 were randomly and evenly divided into control group and observation group. Patients in the control group were only treated with clomiphene. On the basis of the treatment in control group, human chorionic gonadotropin was added in the treatment of observation group. The changes of E, FSH, LH, PRL levels were compared between two groups before and after the treatment. Clinical curative effects of patients in the two groups was evaluated. Adverse reactions during treatment in two groups were observed and recorded. The incidence of adverse reactions was calculated.
Serum E, FSH, LH and PRL levels in the two groups decreased significantly after treatment compared with that before treatment. The difference is statistical significant ( < 0.05). After the treatment, E, FSH, LH and PRL levels in the observation group were lower than that in the control group and the difference is statistical significant ( < 0.05). Total effective rate was 64.44% in the control group and 93.33% in the observation group. There were statistically significant difference in clinical curative effects in the two groups ( < 0.05). Different degrees of adverse reactions were found in both groups during treatment, such as nausea, vomiting, anorexia, liver dysfunction. There were 2 cases of nausea, 2 cases of vomiting, 3 cases of anorexia and 1 case of liver dysfunction from the 45 patients in control group. The total incidence of adverse reactions was 17.78% (8/45). There were 1 case of nausea, 1 case of vomiting, 1 case of anorexia and no liver dysfunction from the 45 patients in observation group. The total incidence of adverse reactions was 6.67% (3/45). The total incidence of adverse reactions in the observation group was significantly higher than that in the control group and the difference was not statistically significant ( > 0.05).
Combined use of human chorionic gonadotropin can significantly reduce serum E, FSH, LH and PRL levels, improve clinical curative effects and reduce the incidence of adverse reactions. Human chorionic gonadotropin has high application value on the treatment of polycystic ovary syndrome.
分析人绒毛膜促性腺激素联合克罗米芬对多囊卵巢综合征患者血清E、FSH、LH及PRL水平的影响。
选取2015年1月至2016年3月收治的90例多囊卵巢综合征患者，随机均分为对照组和观察组。对照组患者仅采用克罗米芬治疗，观察组在对照组治疗基础上加用人绒毛膜促性腺激素。比较两组治疗前后E、FSH、LH、PRL水平变化，评估两组患者的临床疗效，观察并记录两组治疗期间的不良反应，计算不良反应发生率。
两组治疗后血清E、FSH、LH及PRL水平均较治疗前显著降低，差异有统计学意义（P<0.05）。治疗后，观察组E、FSH、LH及PRL水平低于对照组，差异有统计学意义（P<0.05）。对照组总有效率为64.44%，观察组为93.33%，两组临床疗效差异有统计学意义（P<0.05）。两组治疗期间均出现不同程度的不良反应，如恶心、呕吐、厌食、肝功能异常。对照组45例患者中，恶心2例、呕吐2例、厌食3例、肝功能异常1例，不良反应总发生率为17.78%（8/45）。观察组45例患者中，恶心1例、呕吐1例、厌食1例，无肝功能异常，不良反应总发生率为6.67%（3/45）。观察组不良反应总发生率低于对照组，但差异无统计学意义（P>0.05）。
人绒毛膜促性腺激素联合使用可显著降低血清E、FSH、LH及PRL水平，提高临床疗效，降低不良反应发生率，在多囊卵巢综合征治疗中具有较高的应用价值。
